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Abstract
Background: Non-specific binding to biosensor surfaces is a major obstacle to quantitative analysis of selective retention of
analytes at immobilized target molecules. Although a range of chemical antifouling monolayers has been developed to
address this problem, many macromolecular interactions still remain refractory to analysis due to the prevalent high degree
of non-specific binding. We describe how we use the dynamic process of the formation of self assembling monolayers and
optimise physical and chemical properties thus reducing considerably non-specific binding and allowing analysis of specific
binding of analytes to immobilized target molecules.
Methodology/Principal Findings: We illustrate this approach by the production of specific protein arrays for the analysis of
interactions between the 65kDa isoform of human glutamate decarboxylase (GAD65) and a human monoclonal antibody.
Our data illustrate that we have effectively eliminated non-specific interactions with the surface containing the immobilised
GAD65 molecules. The findings have several implications. First, this approach obviates the dubious process of background
subtraction and gives access to more accurate kinetic and equilibrium values that are no longer contaminated by
multiphase non-specific binding. Second, an enhanced signal to noise ratio increases not only the sensitivity but also
confidence in the use of SPR to generate kinetic constants that may then be inserted into van’t Hoff type analyses to
provide comparative DG, DS and DH values, making this an efficient, rapid and competitive alternative to ITC measurements
used in drug and macromolecular-interaction mechanistic studies. Third, the accuracy of the measurements allows the
application of more intricate interaction models than simple Langmuir monophasic binding.
Conclusions: The detection and measurement of antibody binding by the type 1 diabetes autoantigen GAD65 represents
an example of an antibody-antigen interaction where good structural, mechanistic and immunological data are available.
Using SPRi we were able to characterise the kinetics of the interaction in greater detail than ELISA/RIA methods.
Furthermore, our data indicate that SPRi is well suited to a multiplexed immunoassay using GAD65 proteins, and may be
applicable to other biomarkers.
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Introduction
Surface plasmon resonance imagery (SPRi) [1,2] is a label free
technique that avoids the use of fluorescence or radioactive
labelling and offers a comparable dynamic range of detection, as
well as access to kinetic constants not obtained by end point assays
such as Radioimmunoassay (RIA). Furthermore it is a truly
multiplexed assay, allowing the detection and measurement of
ligand binding using a wide-range of immobilised target molecules
simultaneously and in real-time. Performing a large amount of
assays concurrently on one sensor surface offers a clear solution to
problems of variability [3]. Finally, the application of micro
fluidics opens up the exciting possibility of performing biosensor-
based immunoassays using a range of antigens and tens-to
hundreds of antibody/serum samples on one single chip.
A major stumbling block to the goal of achieving high
throughput, rapid, quantitative analysis of peptide microarrays
using SPRi is the difficulty of eliminating non-specific interactions
with the surface containing the microarray target molecules. We
have devised a novel surface chemistry (Nogues et al., submitted) in
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interface with the SPRi device in such a way that non-specific
interactions between solution bound macromolecules and the
surface are essentially non existent. This approach, optimised for
protein-nucleic acid interactions was thus applied here to study the
interaction between the 65kDa isoform of glutamic acid
decarboxylase (GAD65) and a monoclonal antibody.
GAD65, but not GAD67, is a major autoantigen and
autoantibodies to GAD65 are detected at high frequency in
patients with newly diagnosed type 1 diabetes (T1D) (,80%) [4].
Autoantibodies to GAD65 are considered an important diagnostic
marker and are highly effective for predicting the development of
T1D [5]. We reasoned that studying the interaction between
GAD65 and monoclonal antibodies using SPRi might offer several
insights. First, the recent crystal structure determination of both
GAD65 and GAD67 [6] allowed existing epitope mapping studies
[7,8,9] to be placed in a molecular context [7,10,11]. Structural
knowledge of GAD65 also provides a higher level of control over
its immobilisation on the biosensor surface. We are thus now in a
position to probe the precise location and composition of these
epitope sites. Second, establishing the binding kinetics of the
GAD65-antibody interaction may pave the way for the develop-
ment of a SPRi-based, high-throughput immunoassay for T1D.
Measurement of autoantibodies against islet beta cell antigens is
performed in many laboratories throughout the world, and
repeated testing for combinations of b-cell autoantibodies is a
major component of studies examining the progression to diabetes.
At present such immunoassays (typically RIA and ELISA) are
costly and labour intensive, as they are performed individually,
antigen by antigen. However a single test for a diabetes-associated
autoantibody to a single autoantigen cannot form the basis of an
important clinical decision. Therefore screening for these
autoantibodies should be performed using a range of antigens
during different times in the disease process, and for disease
prediction may have to be performed at distinct ages in order to
achieve maximal predictive sensitivity and specificity. As such
there is a pressing need for the development of novel validated
immunoassays that are rapid, cheap, and high-throughput.
A multiplexed SPRi-based optical biosensor assay potentially
offers many advantages over RIA and ELISA and has the
potential to realize the high-throughput screening described
above. We therefore decided to investigate the interaction between
GAD65 and antibody using SPRi.
Methods
Preparation of protein chips
Proteinchipswerepreparedonaglassprism(highrefractiveindex
n 1.7) activated by Reactive Ion Etching (RIE) prior to the thermal
evaporation of a 50 nm gold layer as described in Nogues et al.,




COOH was adsorbed on the gold surface as described previously
[12].Priortoproteindepositiontheprismswerethoroughlyrinsedin
pure ethanol for 20 min. The thiol coupling surface was prepared
using a thiol coupling kit from Biacore following the standard
Biacore protocol; the carboxylated surface was activated by
incubation with a mixture of 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC) (final concentration=200 mM),
N-hydroxysuccinimide (NHS) (final concentration=50 nM) for
5 min at room temperature. A second incubation with 2-(2-
pyridinyldithio) ethaneamine hydrochloride (PDEA) (final concen-
tration=175 mM) for 5 min at room temperature produced a thiol
activated surface. Un-reacted activated carboxyl groups on the
surface were blocked by incubation with ethanolamine (1M at
pH 8.5) for 10 minutes.
The GAD65 protein was dialysed against phosphate buffered
saline (PBS) in order to remove mercaptoethanol in the storage
buffer and aliquots (100nL) at a final concentration of 0.5 mg/ml
GAD65 were then deposited onto the fresh pre-treated prism
surface using the Hamilton starlet robot and a modified pin tool
protocol that minimised contact of the pin tool with the gold
coated surface. Following GAD65 immobilization on the pre-
treated surface via the covalent coupling of the thiol groups of the
protein to the carboxylated-terminal of the surface, un-reacted
groups on the surface were blocked as described in [13]. The
prism was left for two minutes at room temperature in a sealed
Petri dish at 100% relative humidity to prevent the spots from
drying. Moreover, in order to reduce evaporation during the
incubation, the protein solution contained 5% glycerol. The prism
was then directly inserted into the SPRi apparatus and PBS buffer
was immediately flowed across the surface at 25 ml/min.
Preparation of GAD65 and mutants
Details of the expression and purification of recombinant
human GAD65 have been published previously [6]. We used an
N-terminally truncated form of GAD65 that lacked the first 89
residues; the N-terminal truncation facilitated purification because
this region is hydrophobic and highly susceptible to proteolysis,
and did not affect enzymatic properties [6] nor reactivity with
specific antisera [14,15,16]. The proteins were expressed in
Saccharomyces cerevisiae as fusions to a C-terminal hexahistidine
tag, and purified from the cell lysate by immobilized metal affinity
chromatography and size exclusion chromatography in the
presence of glutamate and pyridoxal-59-phosphate (PLP).
Preparation of the monoclonal antibody GAD1
The mouse mAb GAD1, prepared from a BALB/c mouse
immunized with partially purified chicken brain GAD [17] was a
gift from M. Rowley (Monash University).
SPR imaging setup
The SPRi machine was purchased from GenOptics. The
biological interface consists of a prism surface coated with a thin
layer (,50nm) of gold. An evanescent field referred to as a
plasmon wave is created at the interface of this gold-coated surface
and the dielectric from a light beam when the light beam arrives at
the interface at an angle of total internal reflection (TIR). At TIR
there is a resonance effect, leading to a decrease in reflectance at a
given angle. This is measured by imaging the entire reflected light
from a monochromatic polarized electroluminescent diode using a
camera linked via a dedicated optical system. Thus the whole
surface of the imaged field containing many discrete spots with
immobilised ligands may be analysed simultaneously. A micro-
cuvette system allows material to be flowed across the surface and
the SPR response at predetermined spots can be assessed in
parallel by a time resolved CCD that captures changes in
percentage reflectivity at selected spots on the surface. These
changes, averaged across the surface of each spot as a function of
time, are related to changes in concentration of mass at each spot,
and thus provide access to the kinetics of interactions at the surface
at each immobilised ligand. A characteristic of this technique
compared to other SPR based devices is that non-specific
interactions of the molecules directly with the surface around
selected spots can be simultaneously quantified and compared with
specific interactions occurring with the target material in the spots,
assuming that the amount of non specific interaction inside and
outside the spots are identical. A recent study has shown that
SPRi of GAD65-Antibody Binding
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Biacore SPR apparatus or from the SPRi apparatus are
comparable when using identical surfaces and conditions [2].
Interactions with anti-GAD antibodies
GAD1 antibody (200 ml at various concentrations) was flowed
across the immobilised GAD65 proteins in the SPRi apparatus at
20ml/ml at room temperature in PBS buffer.
Data analysis
Prism software was used to fit curves and obtain apparent rate
constants. Curves were fitted to a simple Langmuir binding model
to obtain kinetic constants. The apparent dissociation rate
constant koff may be obtained by fitting the dissociation phase to
a simple exponential expression where the relative change in
resonance response (R) as a function of time (t) with respect to R
at time t=0, (R(0)), results from Rt~R0 exp
{koff t ðÞ and the
apparent association rate constant kon is obtained from
Rt~Rmax 1{exp
{ kon C ½  zkoff )t ðÞ

at a given protein concentra-
tion of C ½  , where Rmax is the response at steady state. The
calculated Kd is simply the ratio of
koff
kon
. Three spots were analysed
and the data represents the average of values obtained for these
three spots.
Results and Discussion
The biochip surface that we have developed (Nogues et al.,
submitted) consists of a 50 nm thick gold surface functionalised
with hydroxyl-terminated tetra (ethylene glycol) (EG4-OH) to
which the proteins had been linked via cysteine residue 101 on
GAD65 (Figure 1). Typical images of the interaction of the
antibody (4.8 nM) as it flows across the spots containing the
immobilised GAD65 protein are shown in Figure 2. The images
are differential images and are taken every two seconds during the
experiment. The background is low and this is also evident from
curves in Figure 3A showing the % reflectivity changes for the wild
type protein GAD65 containing spot and background spot as
antibody passes over the surface. At relatively low concentrations
Figure 1. Structural characteristics of GAD65. Location of Cys residues (orange) on the GAD65 molecule. GAD65 molecules are coupled to the
biosensor using Cys101 and coupling agent/linker. Domains are coloured separately. Putative epitope regions are indicated by red ellipses. Cysteine
residues are indicated in orange, showing their accessible surface area (ASA), Cys101 being the only cysteine residue accessible for coupling to the
biosensor surface. The PDEA coupling agent is indicated by black sticks.
doi:10.1371/journal.pone.0012152.g001
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(Figure 3A) from which apparent rate constants (shown in the
legend to Figure 3) could be calculated. At these concentrations of
antibody the protein GAD65-antibody interaction gave an overall
apparent equilibrium dissociation constant (Kd) of 1.37 nM. We
note that these values are somewhat different from values reported
previously in the literature for this type of interaction [18]; we
consistently found lower equilibrium dissociation constants
essentially due to more rapid association rates that we measure
here. There may be many explanations for this related to the
difference in the immobilisation procedure, the architecture of the
SPR machine, and so forth. However we were surprised to note
that at higher concentrations of antibody (48nM) the binding
phase became multiphasic or at least biphasic (Figure 3B). This
observation was clearly not due to non-specific binding to the
surface (Figure 3B shows a difference curve after subtraction of
background), and indeed the observation of multiphasic binding is
due precisely to the fact that we have very low non-specific binding
to non target areas on the surface. We note that the concentrations
of anti-GAD antibody used in the Biacore study of [18] were in
excess of 500nM, which is 10 to a 100 fold in excess of the values
that we use in the current manuscript and that this strongly
suggests that the values obtained in [18] were somehow influenced
by a degree of non specific binding, if not necessarily to the surface
then perhaps to an abnormal form of the immobilised GAD.
In order to illustrate the degree of antifouling conferred by the
General Liquid Interface Specific Surfaces (GLISS) we in fact
passed human serum across two types of surface, one consisting of
a classical self assembling monolayer (SAM) constructed from
undecanoic acid as described in [2], and the other using the
GLISS surfaces used in the current GAD65 study. As can be seen
in Figure 4 there is a qualitative and quantitative difference
between non-specific binding to the two surfaces with a much
reduced binding to the GLISS surface. The almost negligible
amount of material retained at the GLISS surface compared to the
classical SAM surface is even more evident from the SPR curves
derived from the images.
The available crystallographic structure of GAD65 [6] allowed
the selection of a suitable method of coupling of the protein to the
chip. Specifically, coupling using surface-exposed cysteine residues
in the N-terminal domains allowed the molecule to be immobilised
such that the putative antibody epitopes in the C-terminal and
PLP domains are exposed and accessible by an antibody molecule
(Figure 1). The dimeric architecture of GAD65 presents a
challenge for immobilization, since the 2-fold symmetry may
place equivalent residues in each monomer on opposite sides of the
dimer. There are only two cysteine residues that are on or near the
protein surface (Cys101 and Cys304). Cys304 is relatively buried,
having only 22 A ˚ 2 solvent accessible surface area. In addition, its
sidechain points inwards towards the body of the protein.
Coupling would thus require a significant structural reorganisa-
Figure 2. Difference images obtained from SPRi of antibodies
binding to GAD65 immobilised at a gold/GLISS surface. Spots
(400 mm diameter) containing GAD65 protein were immobilised by
spotting at the surface using Hamilton Starlet equipped with a PinTool
tip and modified software. GAD1 antibody (4.8 nM in 200 ml PBS) was
flowed across the surface at 20 ml/min as described in Methods and
differential images obtained using the GenOptics SPRi device. The red
circle illustrates the area that is generally chosen to calculate the pixel
density at any given time in order to generate curves of the type shown
in Figure 3.
doi:10.1371/journal.pone.0012152.g002
Figure 3. Changes in % reflectivity as a function of time as
GAD1 antibody reacts with immobilised GAD65 protein. Curves
were generatedfromcalculating thechange in % reflectivityin time across
thespotsofthesortshowninFigure2.A)GAD1antibody(4.8 nM)injected
over the surfaces. The wtGAD65 curve was fitted to a simple binding
model (red line) as described in Data Analysis to give the following






21 from which an overall equilibrium dissocia-
tion constant, Kd of 1.3760.06 nM, could be calculated. The background
curve is taken from changes in surface pixel density at equivalent areas on
the surfaces not containing immobilised GAD65; B) GAD1 antibody (48nM)
injected over the surfaces. The association and dissociation phases gave a
poor fit to a single binding site model and were clearly not monophasic.
doi:10.1371/journal.pone.0012152.g003
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each monomer) are on opposite faces of the dimer, precluding
coupling at both sites simultaneously without massive structural
reorganisation. Although we cannot discount some coupling at
only one Cys304 residue at a time (e.g., ‘‘half occupancy’’), its low
exposure, stereochemistry and location make it a highly unlikely
candidate for coupling to the linker. Conversely, Cys101 is highly
exposed on the surface of the protein (140 A ˚ 2 solvent accessible
surface area). It is located in the N-terminal domain very close
(within 0.15 nm) to its ‘‘symmetry-mate’’ in the dimer. The high
exposure and location of Cys101, therefore, make it a highly likely
candidate for linker coupling. The high probability of this mode of
coupling now allows us to confidently pursue the immobilization of
several GAD65 mutants on a single chip. For example we envisage
that engineering epitopes on GAD65 may pave the way for
improved diagnostic tests for type 1 diabetes using a panel of
Figure 4. Differential binding to SPRi surfaces. Two independent surfaces were created either using classical SAM constructed from undecanoic
acid as described in [2], or the GLISS protocol described here. Serum (stock concentration 60mg/ml diluted to a final concentration of 0.6 mg/ml) in
PBS was passed across the surfaces at 25 ml/min. The three images for each surface refer to images prior to, during and after injection of the serum. A)
Differential images of classical undecanoic based SAM surfaces B) Differential images of GLISS prepared surfaces C) Changes in % reflectivity as a
function of time derived from images of the type shown in A and B.
doi:10.1371/journal.pone.0012152.g004
SPRi of GAD65-Antibody Binding
PLoS ONE | www.plosone.org 5 August 2010 | Volume 5 | Issue 8 | e12152antibodies as well as human sera. The ability to couple multiple
GAD65 proteins on the same chip and measure antibody binding
in a reproducible and rapid fashion may ultimately lead to a novel
SPRi-based diagnostic immunoassay for type 1 diabetes.
We clearly advocate the use of engineering surface exposed
cysteines for immobilisation but recognize that this may not always
be possible. A number of alternatives are available, and generally
in SPR, coupling using amines, for the most part through
accessible lysines, is advocated. It must be noted however, that this
generally results in a reduced degree of activity of the immobilised
target that may render quantitative analysis difficult. The GLISS
surfaces used here may easily be functionalised with carboxyl, thiol
or amine groups thus permitting a wide range of immobilisation
techniques. However we would like to stress that although the
expedient of engineering solvent accessible thiols is somewhat
limiting it does optimise accessibility and that whilst this may
restrict general applicability we strongly suggest that immobilisa-
tion strategies that aim at increasing accessibility and orientation
be elaborated rather than blind immobilisation through solvent
accessible amines for example. Alternatively one can immobilise
on the GLISS surfaces, specific antibodies or haptens either
through accessible cysteines or via other coupling techniques, that
then allow mild capture of the target molecules.
Although the purpose of the present study was not to explore
the detection levels of the SPRi technique we could detect and
quantify GAD65-anti-GAD65 interactions between approximately
10
10 molecules of target GAD65 on the surface and antibody at
4nM concentration in solution. Our limit of detection as discerned
from the signal to noise ratio suggests that we can detect a change
of approximately 0.01% reflectivity that corresponds to levels of
detection of around 30 to 40 ng/ml of protein in solution.
We have characterised the binding of wild type GAD65 to the
GAD1 monoclonal antibody using SPRi. Our data illustrate that
we have effectively eliminated non-specific interactions with the
surface containing the immobilised GAD65 molecules. The
implications of this are far reaching; in short not only does this
approach obviate the dubious process of background subtraction
but gives access to more accurate kinetic and equilibrium values
that tend towards more affine measurements since any multiphase
behaviour can be separated from non-specific binding. On a
broader level, an enhanced signal to noise ratio increases not only
the sensitivity but also confidence in the use of SPR to generate
kinetic constants that may then be inserted into van’t Hoff type
analyses to provide comparative DG, DS and DH values, making
this an efficient, rapid and competitive alternative to ITC
measurements used in drug and macromolecular-interaction
mechanistic studies. Finally, and this is particularly evident here,
the accuracy of the measurements allows the application of more
intricate interaction models than simple Langmuir monophasic
binding. The observation that monoclonal antibodies can use
multiple binding modes is intriguing. We are currently applying
the technology developed here to analyse monoclonal antibody
binding to microarrays containing selected mutants of GAD65
(Buckle et al. in preparation). The implications are that
intramolecular rearrangements associated with antibody binding
may be involved.
Conclusions
The detection and measurement of antibody binding by the
type 1 diabetes autoantigen GAD65 represents an example of an
antibody-antigen interaction where good structural, mechanistic
and immunological data are available. Using SPRi we were able to
characterise the kinetics of the interaction in greater detail than
ELISA/RIA methods. Furthermore, our data indicate that SPRi is
well suited to a multiplexed immunoassay using GAD65 proteins,
and may be applicable to other biomarkers.
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